H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Y-Mabs Therapeutics (NASDAQ:YMAB) Inc on Monday, setting a price target of $65, which is approximately 21.50% above the present share price of $53.5.
Burns expects Y-Mabs Therapeutics Inc to post earnings per share (EPS) of -$0.82 for the fourth quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Y-Mabs Therapeutics, with an average price target of $58.33.
The analysts price targets range from a high of $71 to a low of $45.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$32.64 million. The company's market cap is $2.2 billion.
According to TipRanks.com, H.C. Wainwright analyst Robert Burns is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 58.6% and a 84.00% success rate.
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company's services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.